ウェビナー動画：Boehringer Ingelheim社、バイオ医薬品開発の課題解決による細胞株開発のイノベーション
バイオ医薬品の生産において、高性能で安定した細胞株の開発は依然として重要な課題であり、早期の生産適合性評価が最適な候補選定において重要な役割を果たします。本講演では、細胞株ワークフロー全体で使用していたNGSのデータを統合・一元管理することで、mRNA変異の検出、ゲノムへの遺伝子挿入部位の特定、目的分子を発現するクローンの選定といった主要な課題を解決する包括的なアプローチを紹介しています。
The development of robust and high-performing cell lines remains a central challenge in modern biopharmaceutical production of complex biologics. Early developability assessment plays a critical role, allowing teams to identify optimal pools before picking the final candidate and entering full cell line development.
In this webinar, Simon Fischer, Head of Cell Biology and Senior Principal Scientist at Boehringer Ingelheim, presents a comprehensive approach to overcoming 3 common challenges through the systematic integration of next-generation sequencing (NGS) technologies across the cell line development workflow:
- Which clones exhibit mutations on messenger RNA of therapeutic transgenes?
- How to accurately identify the genomic positions of all vector integrations?
- Which of my thousands of clones express the correctly assembled molecule?
The presentation highlights how NGS replaces legacy analytical methods such as Sanger sequencing, Southern blotting, and qPCR, offering significantly improved resolution, sensitivity, and turnaround times. These efforts were underpinned by the implementation of Genedata Selector®, which provided the foundation for standardized workflows, robust data integration, and efficient analysis across the NGS pipeline.
Get insights on:
- How NGS replaces legacy methods for higher resolution and sensitivity
- Reducing development risk by early, data-driven clone selection
- Enhancing stability and performance by controlled transgene integration
- How integrated data platforms enable scalable analytics and future AI applications
